Transitioning from clozapine to Cobenfy (xanomeline-trospium chloride) in treatment resistant schizophrenia and clozapine induced OCD
Abstract Background Treatment-resistant schizophrenia (TRS) is defined as nonresponse to at least two adequate antipsychotic trials at therapeutic doses for six or more weeks. Currently, clozapine is the only antipsychotic approved for TRS by the FDA and a plethora of evidence indicates that it is t...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2026-05-01
|
| Serija: | BMC Psychiatry |
| Teme: | |
| Online pristup: | https://doi.org/10.1186/s12888-026-07795-7 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|